Endocrine Abstracts

Introduction: Glargine is an analogue insulin with a flat pharmacokinetic profile and duration of action of 24 h providing stable ‘background’ insulin on which fast acting insulin can be added during meal times. Clinical trials have indicated that this leads to more satisfactory and stable glycaemic control with reduced frequency of hypoglycaemia. We carried out a prospective audit to see if these reported benefits are confirmed in routine clinical practice.<p cl...

Objective: PCOS affects approximately 10% of women of reproductive age. We have audited the management of women attending the multidisciplinary PCOS clinic at the Royal Berkshire Hospital which was set up in September 2002.Methods: Data on women attending the PCOS clinic at the Royal Berkshire Hospital between September 2002 and September 2004 were analysed. Points investigated were: baseline characteristics, adequacy of investigations and efficacy of tr...

Glargine is an analogue insulin which has a peakless action profile over approximately 24 hours. As a result it has been shown to reduce the frequency of hypoglycaemia thereby enabling achievement of tight glycaemic control. This is important during pregnancy in order to lower the risk of foetal malformations.Method: 17 women, mean age 28 years, with type 1 Diabetes Mellitus on a basal bolus regimen including Glargine became pregnant between January 2004...

Aim: To audit radioactive iodine (RAI) treatment.Methods : A retrospective audit of thyrotoxic patients, who attended the one-stop RAI clinic, between April 2005 and February 2006.Results: We included 74 patients (60 females, 14 males) with a median age 54 (22–85) years.Before RAI: Smoking history was recorded in 19/74(26%) patients. 44/74(59%) patients received drug treatment for two years or mor...